drugset / Trial / NCT06545110

Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

NCT06545110

Phase 1 Active not recruiting 120 enrolled South Valley University
RandomizedParallel-groupSingle-blindTreatment

Summary

Assess serum and tissue retinol binding protein 4 in patients with severe alopecia areata in correlation with healthy individuals . Estimate genetic profile of retinol binding protein4 in severe alopecia areata patients Assess possible role of retinol binding protein 4 genetic mutation in response to barcitinib treatment in patients with severe alopecia areata .

Timeline

Start
2023-09-01
Primary completion
2024-09-30
Completion
2024-10-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Baricitinib Small molecule 2 mg Oral
Comparator Baricitinib Small molecule 4 mg Oral

Indications